Internal medicine (Tokyo, Japan) · 2026
Isavuconazole Therapy for Nasal-Cerebral Mucormycosis with High Isavuconazole MIC.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mori Takeo, Kamiyama Kazuhisa, Koyama Sakura, Nakase Dai, Nakamura Yusuke, Sato Takahiro, Miyazaki Taito, Maeda Tadashi, Nakamura Misaki, Sasaki Masakazu, Watanabe Akira, Yoshizawa Sadako, Tateda Kazuhiro, Sasaki Yosuke
Аннотация
Mucormycosis is a severe infection that requires prompt antifungal therapy. Although liposomal amphotericin B (L-AMB) is the standard treatment, its toxicity may limit its use. We report the case of a patient with diabetes mellitus and rhinocerebral mucormycosis who developed brain abscesses despite L-AMB and surgical interventions. After switching to isavuconazole (ISCZ) and continuing surgical management and optimization of underlying conditions, clinical and radiological improvements were observed. Although partial maxillary bone loss occurred during follow-up, the ISCZ was continued for more than one year without adverse events, and the patient remained clinically stable. Notably, although the isolate showed an ISCZ MIC >8 μg/mL, a clinical improvement was observed with multidisciplinary management.